In patent litigation, expert witnesses play a crucial role in providing specialized knowledge to the court. In a recent case where Osseo...

The recent case involving United Therapeutics' patent on Tyvaso and Liquidia's Yutrepia sheds light on the complexities of patent law....

Recent cases show the U.S. Patent and Trademark Office director's interest in using director review to address substantive issues like...

The Court of Appeals for the Federal Circuit has sparked debate following a recent ruling on the Patent Trial and Appeal Board's (PTAB)...

United States Patent and Trademark Office Director Kathi Vidal's recent sanctions decisions have been notable for their seriousness and...

The U.S. Supreme Court's decision to no longer give deference to government agency interpretations could lead to challenges against U.S....

The Patent Trial and Appeal Board (PTAB) has seen a steady increase in the invalidation rate of patents in the past five years, reaching...

The U.S. Patent & Trademark Office (PTO) has introduced new rules enhancing the independence of administrative patent judge (APJ) panels....

So far in 2024, Director Review decisions have shifted from primarily sua sponte DRs to party-initiated DRs. In addition, there has been...

Lynk Labs has presented an argument to the Federal Circuit, asserting that patent applications should only be utilized to invalidate...

United States Patent and Trademark Office Director Kathi Vidal's recent decision emphasizes the importance of General Plastic factor 1 in...

The NPRM proposals align with interim guidance on requesting director review for key AIA trial decisions. Following the Arthrex v. Smith...